UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in DaVita Inc. $DVA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 16.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 126,765 shares of the company’s stock after selling 24,548 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.20% of DaVita worth $28,203,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DVA. Value Investment Professionals LLC lifted its holdings in shares of DaVita by 2.0% in the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after buying an additional 50 shares in the last quarter. Kesler Norman & Wride LLC grew its stake in DaVita by 0.8% during the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after acquiring an additional 55 shares in the last quarter. Gen Wealth Partners Inc increased its holdings in DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after acquiring an additional 80 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Finally, Orion Porfolio Solutions LLC grew its position in shares of DaVita by 4.4% during the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after purchasing an additional 99 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Up 1.5%

DVA stock opened at $182.00 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The stock has a market capitalization of $11.61 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 0.46 and a beta of 0.83. The firm’s fifty day simple moving average is $209.28 and its two-hundred day simple moving average is $184.28.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research reports. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and lifted their target price for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday, August 7th. Barclays boosted their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Finally, UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.